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Background: Increasing lymph node ratio (LNR) (ratio of metastatic lymph nodes to the total number of harvested lymph nodes)
and extramural vascular invasion (EMVI) have been proposed as adverse prognostic indicators in colorectal cancer, although their
use remains variable and controversial. The aim of the present study was to assess the prognostic value of LNR and EMVI in
predicting survival for patients undergoing curative colon cancer resection.
Methods: Between 2006 and 2012, 922 patients underwent curative colon cancer resection. Surgical technique and pathological
assessment did not change during the study period. Clinical and pathological data were collected from a prospectively
maintained database. The primary outcome measure was overall survival and disease-free survival. LNR was separated into five
categories based on three previously calculated cutoff values: LNR 0 (no lymph nodes involved), LNR 1 (ratio 0.01o0.17), LNR 2
(ratio 0.18–0.41), LNR 3 (ratio 0.42–0.69), and LNR 4 (ratio 40.70).
Results: Nine hundred and twenty-two patients underwent colon cancer resection. The median follow-up for survivors was 52.8
months (IQR 34.6–77.6). The median total number of lymph nodes harvested was 16 (IQR13-22). On multivariate analysis, both pN
and LNR were strongly associated with overall and disease-free survival. Using the Akaike information criterion (AIC), LNR had
greater prognostic value compared with pN. For overall survival, compared with patients in LNR category 0, hazard ratios (95% CI)
for those in categories 1, 2, 3 and 4 were 1.37 (1.03,1.82), 2.37 (1.70,3.30), 2.40 (1.57,3.65) and 5.51 (3.16,9.58), respectively. For
disease-free survival, patients had hazard ratios (95% CI) of 1.78 (1.25,2.52), 3.79 (2.56,5.61), 2.60 (1.50,4.48) and 4.76 (2.21,10.27),
respectively. The presence of EMVI was a significant predictor of decreased overall and disease-free survival (Po0.001).
Conclusions: This study demonstrated, in the presence of high surgical, oncology and pathological standards, EMVI and
increasing LNR were independent predictors of decreased overall and disease-free survival for patients undergoing curative colon
cancer resection. LNR was superior to pN stage in predicting overall and disease-free survival.
Colorectal cancer is the third most common cancer in Europe and
North America (International Agency for Research on Cancer,
2008). Pathological staging not only provides important prognostic
information but also are used to inform discussions and decisions
on the use of adjuvant chemotherapy. The most widely used
colorectal staging tool is the TNM (tumours/nodes/metastases)
system (Sobin and Wittekind, 1997). The fifth edition of TNM
(TNM 5), introduced in 1995, is still predominantly used in the
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United Kingdom to ensure consistency and comparability of data.
Subsequent revisions have not demonstrated an improvement on
prognosis (Ueno et al, 2012).
The presence of lymph node metastases are an important
prognostic factor for survival of patients with colonic cancer. The
current pN stage classifies patients into three categories: pN0
(no lymph node metastases), pN1 (1–3 lymph node metastases),
and pN2 (44 lymph node metastases). A number of studies have
suggested the lymph node ratio (LNR) (defined as the ratio of
metastatic lymph nodes to the total number of harvested lymph
nodes) is a superior prognostic factor compared with the pN stage
(Berger et al, 2005; Rosenberg et al, 2008; Moug et al, 2011; Lykke
et al, 2013). These studies have demonstrated the marked changes
in survival within the pN1 or pN2 categories depending on the
value of LNR. A number of concerns remain, for example: the LNR
categories were arbitrarily defined, colon and rectal cancer were
analysed together, pathological assessment changed over time, the
study period covered a large timeframe, or the use of adjuvant
chemotherapy was not reported.
Additional pathological features have been identified as adverse
prognostic indicators for survival in patients undergoing potential
curative surgery for colorectal cancer. Extramural vascular invasion
(EMVI) has been reported to be an important adverse prognostic
indicator (Courtney et al, 2009; Bhangu et al, 2013). Detection of
EMVI may help improve selection of patients who would benefit
from adjuvant chemotherapy. EMVI is one of the core parameters
to be reported in the minimum data set for colorectal cancer
histopathology reporting as described by the Royal College of
Pathologists (Williams et al, 2007). Despite this, the detection of
EMVI remains highly variable between pathologists (Quirke and
Morris, 2007).
The aim of the present study was to compare the ability of LNR,
EMVI and other pathological factors in predicting overall survival
and disease-free survival for patients undergoing curative colon
cancer resection.
MATERIALS AND METHODS
Inclusion criteria. All patients undergoing curative colon adeno-
carcinoma resection from 2006 to 2012 were included. This
included all patients undergoing elective or emergency surgery.
Colon cancer was defined as a cancer415 cm from the anal verge.
Tumour site was separated into proximal and distal tumours.
Proximal colon cancers were defined proximal to the splenic
flexure. Distal colon cancers were defined as involving splenic
flexure to the rectosigmoid junction. Curative colon cancer
resection was defined as no evidence of metastases on computed
tomography (CT) of the chest, abdomen and pelvis and curative
tumour resection (R0) on pathology assessment.
Patients with metastases, concurrent malignancy and rectal
cancers (o15 cm from the anal verge) were excluded from the
study.
Data collection. Data on patient demographics and tumour
characteristics were obtained from a prospectively maintained
database. Survival data were collated by analysis of a weekly
updated local cancer registry. Adjuvant chemotherapy data were
collected by retrospective review of patient electronic records. All
patients were subject to multidisciplinary review following colonic
resection. The primary outcomes were overall survival (the time
from surgery to the date of death from any cause) and disease-free
survival (the time to death or the discovery of local recurrence or
regional metastasis on follow-up).
Data on age, gender, tumour site, tumour differentiation, TNM
classification, lymph node yield, total number of tumour involved
lymph nodes, LNR, EMVI, adjuvant chemotherapy, overall survival
and disease-free survival were collected. LNR was defined as the
ratio of number of metastatic lymph nodes/total number of
harvested lymph nodes. LNR was separated into five categories
based on three previously calculated cutoff values for LNRs that
had the highest prognostic discrimination of survival in a cohort of
3026 patients with colon and rectal cancer (Rosenberg et al, 2008):
LNR¼ 0 (no lymph nodes involved), LNR¼ 1 (ratio 0.01-0.17),
LNR¼ 2 (ratio 0.18–0.41), LNR¼ 3 (ratio 0.42–0.69), and LNR¼ 4
(ratio 40.70). These values have been validated on a population-
based study of colorectal cancer patients (Rosenberg et al, 2010).
Patients with no lymph nodes involved (LNR¼ 0) were included in
the study to compare survival outcomes with the other four LNR
categories both in the main analyses and sub group analyses.
Clinical management. All patients were subject to multidisciplin-
ary review following colonic resection. Clinical assessment and
staging was based on endoscopic evaluation and CT of the chest,
abdomen and pelvis. Operative technique did not change during
the study period and consisted of complete mesocolic mobilisation
and division of the supplying arteries at their origin. For right-
sided colon cancer resection, more radical mobilisation as
described by Hohenberger et al (2009), involving mesenteric root,
duodenum and pancreatic head mobilisation was not routinely
performed.
Histopathological assessment of the colonic cancer excision
specimens followed a uniform protocol throughout the study
period. The colonic cancer excision specimens were received fresh
in the diagnostic histopathological laboratory, opened along the
antimesenteric border proximal and, when appropriate distal to the
tumour, washed in cold water and then fixed in 10% neutral
buffered formalin for at least 48 h at room temperature prior to
further dissection and block selection. Representative tissue blocks
were embedded in wax, sections were then stained with
haematoxylin and eosin for histopathological diagnosis and when
required tumour sections were also stained with elastic haematox-
ylin and eosin to permit further assessment of EMVI. The tumours
were reported according to the guidelines of Royal College of
Pathologists for the histopathological reporting of colorectal cancer
resection specimens, which incorporates guidance from version
five of the TNM staging system (Williams et al, 2007).
The follow-up programme included outpatient visits every 6
months for 3 years. Blood was takn at these visits to measure liver
function and carcinoembryonic antigen. Imaging was annual CT
scanning (thorax, abdomen and pelvis), with 6 monthly interval
abdominal ultrasound scanning. A follow-up colonoscopy was
performed at 5 years unless it was incomplete at preoperative
assessment. If this occurred, a repeat colonoscopy was performed
in the postoperative period.
Adjuvant chemotherapy was considered for fit patients with
adverse prognostic factors, such as the presence of metastatic
lymph nodes, the presence of EMVI, serosal involvement or poorly
differentiated tumours. The majority of patients with colon cancer
were age 470 years, any decision on the use of adjuvant
chemotherapy considered co-morbidities and the reduced physio-
logical reserve of an older population of patients. During the study
period, suitable patients were offered participation into adjuvant
chemotherapy trials. These were the AVANT study (de Gramont
et al, 2012) and the SCOT study (SCOT-Short Course Oncology
Therapy, 2007). Outside of these trials, suitable patients would
have been considered for oxaliplatin combined with folinic acid/5-
FU or capecitabine.
Statistical analysis. The effect of sex, tumour site, tumour grade, T
stage, N stage, adjuvant chemotherapy, LNR and EMVI on overall
survival and disease-free survival was first examined individually
using Kaplan-Meier survival analysis. Differences in survival
between categories were assessed using the log-rank test.
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The joint effect of these variables upon overall survival was then
examined in a multivariate analysis using Cox’s proportional
hazards regression models. As LNR category and pN are correlated
measures of lymph node status, separate models were developed
for each. These models also controlled for age, EMVI, site, T stage,
tumour grade and adjuvant chemotherapy.
The Akaike information criterion (AIC) provides an objective
way of determining which model among a set of models is best for
a given set of data, with the model with the lowest AIC being the
best for the given data. In the present manuscript, AIC was used to
determine the relative prognostic performance of pN and LNR
models on overall survival and disease-free survival. The model
with the lowest AIC gives the best prognostic value for predicting
overall survival and disease-free survival.
Subgroup analyses by EMVI status were also examined using Cox’s
proportional hazards regression models. These models again controlled
for adjuvant chemotherapy, age, site, pT stage and tumour grade.
All analyses were performed using IBM SPSS version 22.
A P-value o0.05 was used as the level of significance.
Ethics. The project was carried out using anonymised data and
within the remit of ethics approval (ref. nos. 08/S0801/81) from the
North of Scotland research ethics committee.
RESULTS
Nine hundred and twenty-two patients with colon cancer
underwent curative resection. One patient was excluded from
the study as data on overall survival, local recurrence or
metastatic disease were not available. The median follow-up for
survivors was 52.8 months (IQR 34.6–77.6). During the follow-
up period, 345 out of 921 (37.4%) patients died. Local or
metastatic disease was detected in 233 out of the 921 (25.2%)
patients. Clinical, pathological and chemotherapy data are shown
in Tables 1 and 2. The median total number of lymph nodes
harvested was 16 (IQR 13-22). The number of patients withX12
lymph nodes was 776 (84.2%). EMVI was present in 260 (28.0%)
patients.
Univariate analysis. Univariate analysis using the log-rank test
identified the following parameters as statistically significant
predictors of improved overall survival and disease-free survival:
well or moderate tumour differentiation (P¼ 0.002), lower pT
category (Po0.001), distal tumour site (P¼ 0.02), lower pN
category (o0.001), lower LNR (o0.001) (Figures 1 and 2), absence
of EMVI (Po0.001), and elective surgery (Po0.001).
Table 1. Clinical, histopathology and adjuvant chemotherapy characteristics and Cox proportional hazard models predicting
overall survival for patients undergoing curative colon cancer resection
Model One (including pN) (n¼921) Model Two (including LNR) (n¼921)
Variable Patient demographics Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Age, years 75 (66–82)
(median (IQR))
1.02 (1.00, 1.03) 0.007 1.01 (1.00, 1.03) 0.007
Site
Proximala 540 (58.3%) 1 0.12 1 0.20
Distal 381 (41.2%) 0.83 (0.66, 1.05) 0.86 (0.68, 1.08)
Tumour grade
Well/moderatea 791 (85.9%) 1 0.03 1 0.03
Poor/mucinous 130 (14.1%) 1.37 (1.04, 1.82) 1.37 (1.03, 1.82)
T stage
1a 53 (5.7%) 1 0.001 1 0.002
2 82 (8.9%) 1.17 (0.53, 2.59) 1.11 (0.50, 2.48)
3 576 (62.2%) 1.19 (0.60, 2.36) 1.15 (0.58, 2.27)
4 210 (22.7%) 1.93 (0.94, 3.92) 1.84 (0.90, 3.75)
N stage
0a 510 (55.4%) 1 o0.001 NA
1 270 (29.3%) 1.52 (1.17, 1.99) NA
2 141 (15.3%) 2.40 (1.76, 3.28) NA
Lymph node ratio
LNR 0a 510 (55.4%) NA 1 o0.001
LNR 1 (0.01–0.17) 243 (26.4%) NA 1.37 (1.03, 1.82)
LNR 2 (0.18–0.41) 105 (11.4%) NA 2.37 (1.70, 3.30)
LNR 3 (0.42–0.69) 42 (4.6%) NA 2.40 (1.57, 3.65)
LNR 4 (40.7) 21 (2.3%) NA 5.51 (3.16, 9.58)
Extramural vascular invasion
Noa 661 (71.4%) 1 o0.001 1 o0.001
Yes 260 (28.0%) 2.08 (1.62, 2.68) 1.98 (1.54, 2.56)
Adjuvant chemotherapy
Noa 750 (81.5%) 1 0.01 1 0.01
Yes 171 (18.5%) 0.62 (0.42, 0.91) 0.61 (0.41, 0.89)
Total number of lymph nodes 16 (13–22)
(median (IQR))
0.98 (0.96, 0.99) 0.005 0.99 (0.97, 1.00) 0.13
Emergency status
Electivea 739 (80.2%) 1 o0.001 1 o0.001
Emergency 182 (19.8%) 2.43 (1.91, 3.11) 2.53 (1.98, 3.23)
Abbreviations: CI¼ confidence interval; IQR¼ interquartile range; LNR¼ lymph node ratio; NA¼ not applicable.
aReference category.
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Table 2. Clinical, histopathology and adjuvant chemotherapy characteristics and Cox proportional hazard models predicting
disease-free survival for patients undergoing curative colon cancer resection
Model One (including pN) (n¼921) Model Two (including LNR) (n¼921)
Variable Patient demographics Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Age, years 75 (66–82)
(median (IQR))
0.99 (0.97, 1.00) 0.07 0.99 (0.98, 1.00) 0.10
Site
Proximala 540 (58.3%) 1 0.48 1 0.69
Distal 381 (41.2%) 0.91 (0.69, 1.19) 0.95 (0.72, 1.25)
Tumour grade
Well/moderatea 791 (85.9%) 1 0.27 1 0.16
Poor/mucinous 130 (14.1%) 1.22 (0.86, 1.73) 1.29 (0.90, 1.83)
T stage
1a 53 (5.7%) 1 0.001 1 0.001
2 82 (8.9%) 0.87 (0.28, 2.77) 0.84 (0.26, 2.65)
3 576 (62.2%) 1.78 (0.72, 4.42) 1.69 (0.68, 4.18)
4 210 (22.7%) 2.91 (1.14, 7.44) 2.82 (1.10, 7.20)
N stage
0a 510 (55.4%) 1 o0.001 NA
1 270 (29.3%) 1.96 (1.40, 2.73) NA
2 141 (15.3%) 3.35 (2.28, 4.92) NA
Lymph node ratio
LNR 0a 510 (55.4%) NA 1 o0.001
LNR 1 (0.01–0.17) 243 (26.4%) NA 1.78 (1.25, 2.52)
LNR 2 (0.18–0.41) 105 (11.4%) NA 3.79 (2.56, 5.61)
LNR 3 (0.42–0.69) 42 (4.6%) NA 2.60 (1.50, 4.48)
LNR 4 (40.7) 21 (2.3%) NA 4.76 (2.21, 10.27)
Extramural vascular invasion
Noa 661 (71.4%) 1 1
Yes 260 (28.0%) 2.10 (1.55, 2.83) o0.001 2.08 (1.54, 2.81) o0.001
Adjuvant chemotherapy
Noa 750 (81.5%) 1 0.12 1 0.09
Yes 171 (18.5%) 0.73 (0.49, 1.09) 0.70 (0.47, 1.05)
Total number of lymph nodes 16 (13–22)
(median (IQR))
0.98 (0.96, 1.00) 0.02 0.99 (0.97, 1.01) 0.22
Emergency status
Electivea 739 (80.2%) 1 1
Emergency 182 (19.8%) 1.88 (1.39, 2.54) o0.001 1.90 (1.40, 2.57) o0.001
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Number at risk
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Figure 1. Overall survival by lymph node ratio category (LNR 0–4) for






21 5 2 1 0LNR1 = 4
42 17 7 2 1LNR1 = 3
105 43 29 18 5LNR1 = 2
243 152 85 45 20LNR1 = 1
510 389 221 110 37LNR1 = 0
Number at risk
24 48 72 96
Time from operation to death or last follow-up (months)
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LNR = 2 LNR = 3
LNR = 4
Figure 2. Disease-free survival by lymph node ratio category (LNR 0–4)
for patients undergoing curative colon cancer resection.
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Adjuvant chemotherapy and sex were not statistically significant
predictors of overall mortality (P¼ 0.065 and P¼ 0.381,
respectively).
Multivariate analysis. Table 2 shows the results of the two Cox
regression models for overall survival, one including pN and the
other LNR category. Table 3 shows the results of the corresponding
Cox regression models for disease-free survival. There was strong
evidence that, after controlling for other variables, both N stage
and LNR category were associated with overall survival and
disease-free survival. For overall survival, compared with patients
with pN 0, those with pN 1 and 2 had hazard ratios (95% CI) of
1.52 (1.17, 1.99) and 2.40 (1.76, 3.28), respectively. For disease-free
survival, patients had hazard ratios (95% CI) of 1.96 (1.40, 2.73)
and 3.55 (2.28, 4.92), respectively.
For overall survival, compared with patients in LNR category 0,
hazard ratios (95% CI) for those in categories 1, 2, 3 and 4 were
1.37 (1.03, 1.82), 2.37 (1.70, 3.30), 2.40 (1.57, 3.65) and 5.51 (3.16,
9.58), respectively. For disease-free survival, patients had hazard
ratios (95% CI) of 1.78 (1.25, 2.52), 3.79 (2.56, 5.61), 2.60 (1.50,
4.48) and 4.76 (2.21, 10.27), respectively.
The multivariate analyses identified the presence of EMVI as a
statistically significant predictor of decreased overall and disease-
free survival (Po0.001).
Other parameters associated with statistically significant
decreased overall and disease-free survival included: higher pT
category and emergency surgery. The administration of adjuvant
chemotherapy was a significant predictor of improved overall
survival but not disease-free survival in the adjusted analysis.
Using pN in the Cox regression model, the total number of
lymph nodes harvested was associated with significant decreased
overall and disease-free survival. This association was not present
when LNR was used in the model.
Prognostic value of LNR and pN on overall survival. The AIC
was used to determine the relative performance of pN and LNR.
LNR model was found to have lower AIC values for both overall
survival (13.1 points) and disease-free survival (4.4 points),
indicating that LNR may have the greater prognostic value
(Table 4).
Subgroup analysis. The relationship of LNR and EMVI on overall
survival was evaluated using subgroup analyses. Separate Cox’s
proportional hazard regression models were performed for the
LNR categories in patients with and without EMVI (Figures 3 and 4).
LNR categories 2, 3 and 4 were combined because of small
numbers in these individual categories.
Patients with EMVI had a worse overall survival. For both
subgroups (those with and without EMVI), there was a similar
statistically significant relationship (Po0.001) between LNR
categories (LNR 0, LNR 1 and LNR 2-4) and overall survival
(Figures 3 and 4).
DISCUSSION
The present study has shown LNR and EMVI were independent
predictors of overall and disease-free survival for patients under-
going curative colon cancer resection. LNR category was of greater
prognostic value for predicting overall survival compared with pN
category.
A number of studies have reported the prognostic value of LNR
in predicting survival for patients undergoing colorectal cancer
Table 3. Prognostic value of pN and LNR on overall survival
using Akaike information criterion (AIC)
AIC
Base modela 4169.5
Base model plus pN 4144.1
Base model plus LNR 4131.0
Abbreviation: LNR¼ lymph node ratio.
aBase model is a Cox proportional hazards model including the following variables: age,
site, grade, T stage, extramural vascular invasion, adjuvant chemotherapy, total nodes, and
emergency status.
Table 4. Prognostic value of pN and LNR on disease-free
survival using Akaike information criterion (AIC)
AIC
Base modela 2866.9
Base model plus pN 2832.7
Base model plus LNR 2828.3
Abbreviation: LNR¼ lymph node ratio.
aBase model is a Cox proportional hazards model including the following variables: age,







24 48 72 96
Time from operation to death or last follow-up (months)
LNR1cat = 2–4
LNR1cat = 1
100 31 12 7 2
80 42 16 7 3
80 48 14 7 1LNR1cat = 0
Number at risk
LNR = 0 LNR = 1
LNR = 2–4
Figure 3. Overall survival of patients with extramural vascular invasion
by LNR category (LNR 0, LNR 1 and LNR 2–4 together) undergoing






68 52 28 18 6LNR1cat = 2–4
163 127 75 40 18LNR1cat = 1
431 362 225 111 38LNR1cat = 0
Number at risk
24 48 72 96
Time from operation to death or last follow-up (months)
LNR = 0 LNR = 1
LNR = 2–4
Figure 4. Overall survival of patients without extramural vascular
invasion by LNR category (LNR 0, LNR 1 and LNR 2–4 together)
undergoing curative colon cancer resection.
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resection. Different groups have used different methods for
stratifying the LNR categories.
Schiffmann et al (2013), in a cohort of 142 stage III colon cancer
patients, compared LNR with pN category. Using a single LNR
statistical cutoff of 0.2 to separate patients into two groups, the
authors concluded LNR did not improve the prognostic value in
predicting survival. Limitations included the small number of
patients and the variable preoperative staging strategy. No details
of pathological assessment were given. Using only two groups for
LNR may reduce its prognostic value.
Berger et al (2005) stratified patients with stage II and III colon
cancer into four LNR categories based on quartiles. They
demonstrated that LNR was an important predictor of overall
survival when 410 lymph nodes were harvested. There were
marked differences in the 5-year survival between the lowest and
highest LNR categories for patients within the pN1 and N2
categories (19% and 28%, respectively).
From 1988 to 2003, Wang et al (2008) in a population-based
study of 24 477 patients with node-positive colon cancer from the
Surveillance, Epidemiology and End Results cancer (SEER) registry
demonstrated that LNR was a more accurate prognostic method
for staging node-positive colon cancers than the number of positive
lymph nodes. LNR was categorised based on four cutoff points: 1
out of 14, 25%, 50%, 100%. The results of this multi-centre study
need to be interpreted with caution as the clinical and pathological
techniques may change over time or vary between centres. In
addition, not all treatment data were available, including the
administration of adjuvant chemotherapy.
Rosenberg et al (2008), using statistical analysis, identified three
cutoff values for LNR (0.17, 0.41 and 0.69) and demonstrated
superior prognostic impact on overall survival compared with pN
category. There were some limitations to the study in that the study
period covered 25 years (raising concerns regarding changes in
pathological assessment over the time period) and colon and rectal
cancers were analysed together. A follow-up of large population-
based study of colorectal cancer patients by the same leading
author and using the same LNR cutoff values confirmed the strong
independent prognostic value of these LNR categories (Rosenberg
et al, 2010). There were marked differences in the 10-year survival
between the lowest and highest LNR categories for patients within
the pN1 and N2 categories (20% and 50%, respectively). The
authors concluded that LNR should be routinely included in the
pathological reporting.
The present study, in a different patient population, used the
same LNR cutoff values as Rosenberg et al (2008). This
demonstrated the statistically significant difference in overall and
disease-free survival using LNR categories from Rosenberg et al
(2008) for patients undergoing curative colon cancer resection. The
models including LNR category were found to have lower AIC
values (indicating better model fit) than the models including pN
category when predicting overall and disease-free survival. It is not
possible to include both within the same scoring system due to the
relationship between the categories; our results lend support to the
view that LNR should be used instead of pN status. This has several
advantages over other studies: surgical and pathological technique
did not change, adjuvant chemotherapy was controlled for in the
statistical model, and colon cancer was analysed separately.
The optimal total number of lymph nodes harvested for colon
cancer resection is controversial. Despite the lack of evidence, The
Royal College of Pathologists UK recommends a minimum of
12 lymph nodes need to be harvested (Williams et al, 2007).
A number of observational studies have suggested different cutoffs
for total number of lymph nodes to be harvested (Cianchi et al,
2002; Bui et al, 2006; Chen and Bilchik, 2006; Choi et al, 2010).
O’Shea et al (2014) compared total lymph node yield of 3216
patients undergoing surgery for colorectal cancer. The authors
demonstrated an increasing lymph node yield over time (14.91 in
2005 rising to 21.38 in 2012), but this was not associated with
increased number of lymph node-positive cancers. Baxter et al
(2010), in a population study of 11 044 patients with pT3 colon
cancers (SEER registry), reported that the proportion of patients
found to be node positive increases with increasing total lymph
node counts up to 5 or 6 but, at higher lymph node count (X7),
has marginal effects on staging.
Sjo et al (2012), in an observational study, looked at the
prognostic impact of total lymph node harvest and LNR in 950
patients undergoing curative colon cancer resection. The authors
found that, on multivariate analysis, the total number of lymph
nodes was not a prognostic factor when analysed with LNR for
patients with lymph node metastasis. Also, Wang et al (2008) in
the previously mentioned population-based study assessing
patients with node-positive colon cancer concluded that the
prognostic capability of LNR was not dependent on the total
number of lymph nodes.
In the present study, 84% of patients had 412 lymph nodes
harvested. On multivariate analysis, using the LNR model, the total
number of lymph nodes harvested was not associated with overall
survival or disease-free survival.
The presence of EMVI has been shown to be an adverse
prognostic indicator of survival for patients with colorectal cancer.
The majority of studies have focussed on node-negative colorectal
cancers. Courtney et al (2009), in 378 patients undergoing
potentially curative colorectal cancer resection, demonstrated that
the presence of EMVI was associated with a significant decrease in
survival. The authors did not perform any further analysis for
patients with metastatic lymph nodes. Morris et al (2006), in a
population-based study of 1306 patients with node-negative
colonic carcinoma treated with surgery alone demonstrated a
worse prognosis in the presence of EMVI. It is possible that these
studies have concentrated on patients with node-negative
colonic cancers as nodal disease is an indicator for adjuvant
chemotherapy and the presence of EMVI is therefore unlikely to
alter management in these patients. Sternberg et al (1999)
assessed 171 patients with node-positive colorectal cancer and
found that those patients without venous invasion had a better
cancer-related survival compared with those with venous
invasion. Stratifying patients to pN1 and pN2 lymph node
categories did not show any significant cancer-related survival
benefit. The authors concluded that venous invasion was a better
indicator of prognosis than pN status. The authors assessed
colon and rectal cancers together and the study did not control
for administration of adjuvant chemotherapy. The differentia-
tion between intramural and extramural venous invasion was not
routinely made. Betge et al (2012) randomly selected 381
patients with colorectal cancer from 1992 to 2000. Differentia-
tion between intramural and extramural venous invasion was
made. EMVI was detected 14% of patients and a significant
predictor of both disease progression and cancer-specific
survival.
Quirke found in routine UK practice that the detection of EMVI
was poor at 10% (Quirke and Morris, 2007). He felt that a
pathologist should be able to detect EMVI in approximately 30% of
cases. The Royal College of Pathologists have recommended that
EMVI should be detected in at least 25% of cases (Williams et al,
2007).
In the present study, EMVI status was examined in all patients
using the technique recommended by the Royal College of
Pathologists. The incidence of EMVI in this study was 28%. In
this cohort of patients undergoing curative colon cancer resection,
we have demonstrated that the presence of EMVI was a significant
independent predictor of decreased overall survival and disease-
free survival even when adjusted for lymph node status.
A number of studies have found that patients with a low
LNR have a similar long-term survival as node-negative patients.
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Moug et al (2011), in a study of 206 patients undergoing curative
colorectal cancer patients, demonstrated that there was no
statistically significant difference in overall survival between the
two lowest LNR groups (pLNRo0.05 and pLNR 0.05–0.19).
Patients in the pLNR category o0.05 were mainly node negative.
The study did not control for adjuvant chemotherapy and did not
assess for EMVI status. In a prospective nationwide Danish study
of 8901 patients with Stage I-III colon cancer, the 5-year survival
rate in LNR o0.08 was the same as those with node-negative
disease (Lykke et al, 2013). It was not possible to differentiate
between those patients receiving adjuvant chemotherapy.
In this study, which controlled for adjuvant chemotherapy, the
presence of EMVI was associated with a worse prognosis regardless
of lymph node status. For patients with or without EMVI, there
was a similar statistically significant relationship between LNR
categories as the overall sample. However, it was necessary to
combine patients in LNR categories 2-4 due to smaller numbers.
For patients without EMVI, those with low LNR (LNR1) have
improved overall survival compared with those in the LNR 2-4
group. It may be that, on an individual basis for patients with a low
LNR (0.01–0.17), adjuvant chemotherapy can be omitted in those
deemed at risk of developing significant side effects as they have a
relatively good prognosis.
This study has limitations. This was a retrospective review of
routinely prospectively collected data. Although the overall number
of patients in the study was reasonable, the number of patients in
each lymph node category on sub-group analysis of EMVI status
was small. The results of these subgroup analyses should only be
interpreted as exploratory analyses.
CONCLUSION
This study has demonstrated, in the presence of consistently high
surgical, pathological, oncological standards and long follow-up, the
presence of EMVI and increasing LNR were independent predictors of
adverse overall and disease-free survival in patients undergoing
potentially curative colon cancer resection. LNR was superior to pN
stage in predicting overall and disease-free survival. We believe that
LNR and EMVI should be routinely included in the minimum data set
for colon cancer pathological reporting. This would allow improved
prognostic stratification (compared with TNM stage) and may help
influence decisions on adjuvant chemotherapy for more frail patients.
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